SecBot SecBot
8-K ·Filed Aug 4, 2026

RVTY

REVVITY, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000031791-26-000022
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat and raised guidance, particularly the accelerating Diagnostics segment (+11% organic), signal improving end-market demand. The China IDX divestiture simplifies the portfolio and removes a ~6% revenue headwind. Traders should watch for potential multiple expansion as the market prices in the raised guidance and margin recovery. The Life Sciences segment decline (-3% organic) is a modest offset but is being outpaced by Diagnostics strength.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$111.39
T+0 close · Aug 4, 2026 · via day close
Latest settled
+45.31%
T+60 · $161.86
Vs SPY
+44.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $111.39entry
  2. T+1 · 3mo ago +3.26%α +3.46% · $115.02
  3. T+5 · 3mo ago +3.90%α +4.00% · $115.73
  4. T+20 · 3mo ago +13.65%α +14.88% · $126.59
  5. T+60 · 20d ago +45.31%α +44.93% · $161.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revvity reported Q2 2026 adjusted EPS of $1.41, a 19.5% beat vs the $1.22 consensus, on revenue of $730M (above $703.2M consensus). The company raised full-year 2026 pro forma adjusted EPS guidance to $5.30-$5.40 and revenue guidance to $2.83-$2.86B, citing strong Diagnostics segment growth (+11% pro forma organic) and tariff refunds. The filing also confirms a definitive agreement to divest the China Immunodiagnostics business for up to $200M, expected to close by end of 2027. The combination of a significant earnings beat, raised guidance, and portfolio simplification is a clear positive catalyst.

Key Financial Metrics

EPS
$1.41
est $1.22 · +15.6%
Revenue
$729.7M
est $703.2M · +3.8% · +1.3% YoY
Rating
strong beat
Guidance
$2.83B-$2.86B
raised

Key Facts

  • Adjusted EPS from continuing operations of $1.41 vs consensus $1.22 (beat by +15.9%)
  • Revenue of $730M vs consensus $703.2M (beat by +3.8%)
  • Raised FY2026 guidance: pro forma adjusted EPS to $5.30-$5.40 (from $5.20-$5.30) and revenue to $2.83-$2.86B (from $2.81-$2.84B)
  • Diagnostics segment pro forma organic revenue grew 11% YoY; Life Sciences pro forma organic revenue declined 3%
  • Entered definitive agreement to divest China Immunodiagnostics business for up to $200M, expected to close by end of 2027
  • Adjusted operating margin expanded to 28.9% from 26.6% YoY, boosted by $16M in tariff refunds
  • Operating cash flow from continuing operations was $191.9M in Q2, up from $134.3M a year ago

Financial Impact

EPS beat of $0.19 (+15.9%) on consensus of $1.22; revenue beat of ~$27M (+3.8%) on consensus of $703.2M; FY guidance raised by $0.10 on EPS and $20M on revenue at midpoint

revenueepsguidanceoperating margincash flow

Risk Factors

  • Life Sciences segment organic revenue declined 3% YoY, indicating ongoing weakness in that end-market
  • Q2 adjusted EPS includes ~$0.11 from tariff refunds, which may not recur
  • China IDX divestiture closing by end of 2027 is subject to regulatory approvals and could be delayed or modified
  • FY2026 guidance is on a pro forma basis excluding China IDX, creating a comparison complexity

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
52% bullish (25 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000031791-26-000022
Document: q22026proformafinancialsta.htm0000031791-26-000022
Document: pki-20260804.htm0000031791-26-000022
Document: 0000031791-26-000022-index-headers.html0000031791-26-000022
Document: 0000031791-26-000022-index.html0000031791-26-000022
Document: 0000031791-26-000022.txt0000031791-26-000022
8-K Data (Synthetic)0000031791-26-000022

Track record

9 reports on RVTY

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $150.78 Now $148.85 −1.28% settles Dec 15
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $154.39 Now $148.85 −3.59% settles Dec 14
  3. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $163.48 Now $148.85 −8.95% settles Dec 2
  4. Oct 15, 20264w ago Institutional Cluster Neutral 3/10 Entry $154.64 to $158.25 Now $148.85 −3.74% ▲ +2.33% +3.75% vs SPY
  5. Oct 7, 20265w ago SC 13G/A Bullish 4/10 Entry $153.60 to $159.43 Now $148.85 −3.09% ▲ +3.80% +5.13% vs SPY
  6. Sep 23, 20267w ago Insider Cluster Bearish 4/10 Entry $150.61 to $157.29 Now $148.85 +1.17% ▼ −4.43% −4.85% vs SPY
  7. Aug 4, 202614w ago 8-K Bullish 7/10 Viewing Entry $111.39 to $126.59 Now $148.85 +33.63% ▲ +13.65% +14.88% vs SPY
  8. May 5, 202627w ago 8-K Mixed 5/10 Entry $92.30 to $100.39 Now $148.85 +61.27% ▲ +8.76% +3.81% vs SPY
  9. Mar 16, 202635w ago DEFA14A Neutral 3/10 Entry $86.41 to $93.44 Now $148.85 +72.26% ▲ +8.13% +4.35% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026